Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 335

1.

Multiple unilateral subcapsular cortical hemorrhagic cystic disease of the kidney: CT and MRI findings and clinical characteristic.

Yoshida K, Takahashi N, King BF, Kawashima A, Harris PC, Cornell LD, Cornec-Le Gall E, Inoue D, Mizushima I, Kawano M, Thervet E, de Cotret PR, Torres VE.

Eur Radiol. 2019 Feb 26. doi: 10.1007/s00330-019-06057-3. [Epub ahead of print]

PMID:
30806804
2.

Standardizing total kidney volume measurements for clinical trials of autosomal dominant polycystic kidney disease.

Edwards ME, Blais JD, Czerwiec FS, Erickson BJ, Torres VE, Kline TL.

Clin Kidney J. 2019 Feb;12(1):71-77. doi: 10.1093/ckj/sfy078. Epub 2018 Aug 29.

3.

Validation of a Metabolite Panel for a More Accurate Estimation of Glomerular Filtration Rate Using Quantitative LC-MS/MS.

Freed TA, Coresh J, Inker LA, Toal DR, Perichon R, Chen J, Goodman KD, Zhang Q, Conner JK, Hauser DM, Vroom KET, Oyaski ML, Wulff JE, Eiríksdóttir G, Gudnason V, Torres VE, Ford LA, Levey AS.

Clin Chem. 2019 Mar;65(3):406-418. doi: 10.1373/clinchem.2018.288092. Epub 2019 Jan 15.

PMID:
30647123
4.

Progress in the understanding of polycystic kidney disease.

Torres VE, Harris PC.

Nat Rev Nephrol. 2019 Feb;15(2):70-72. doi: 10.1038/s41581-018-0108-1. No abstract available.

PMID:
30607031
5.

Relationship between caffeine intake and autosomal dominant polycystic kidney disease progression: a retrospective analysis using the CRISP cohort.

McKenzie KA, El Ters M, Torres VE, Harris PC, Chapman AB, Mrug M, Rahbari-Oskoui FF, Bae KT, Landsittel DP, Bennett WM, Yu ASL, Mahnken JD.

BMC Nephrol. 2018 Dec 27;19(1):378. doi: 10.1186/s12882-018-1182-0.

6.

Polycystic kidney disease.

Bergmann C, Guay-Woodford LM, Harris PC, Horie S, Peters DJM, Torres VE.

Nat Rev Dis Primers. 2018 Dec 6;4(1):50. doi: 10.1038/s41572-018-0047-y. Review.

PMID:
30523303
7.

Three-dimensional NMR microscopy of zebrafish specimens.

Kline TL, Sussman CR, Irazabal MV, Mishra PK, Pearson EA, Torres VE, Macura SI.

NMR Biomed. 2019 Jan;32(1):e4031. doi: 10.1002/nbm.4031. Epub 2018 Nov 15.

PMID:
30431194
8.

Pro: Tolvaptan delays the progression of autosomal dominant polycystic kidney disease.

Torres VE.

Nephrol Dial Transplant. 2019 Jan 1;34(1):30-34. doi: 10.1093/ndt/gfy297.

PMID:
30312438
9.

A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan.

Chebib FT, Perrone RD, Chapman AB, Dahl NK, Harris PC, Mrug M, Mustafa RA, Rastogi A, Watnick T, Yu ASL, Torres VE.

J Am Soc Nephrol. 2018 Oct;29(10):2458-2470. doi: 10.1681/ASN.2018060590. Epub 2018 Sep 18.

PMID:
30228150
10.

Total Kidney Volume and Autosomal Dominant Polycystic Kidney Disease: A Long-Standing Relationship.

Irazabal MV, Torres VE.

Am J Nephrol. 2018;48(1):65-66. doi: 10.1159/000491026. Epub 2018 Aug 2. No abstract available.

11.

Recent Advances in the Management of Autosomal Dominant Polycystic Kidney Disease.

Chebib FT, Torres VE.

Clin J Am Soc Nephrol. 2018 Nov 7;13(11):1765-1776. doi: 10.2215/CJN.03960318. Epub 2018 Jul 26. Review.

PMID:
30049849
12.

Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.

Edwards ME, Chebib FT, Irazabal MV, Ofstie TG, Bungum LA, Metzger AJ, Senum SR, Hogan MC, El-Zoghby ZM, Kline TL, Harris PC, Czerwiec FS, Torres VE.

Clin J Am Soc Nephrol. 2018 Aug 7;13(8):1153-1161. doi: 10.2215/CJN.01520218. Epub 2018 Jul 19.

PMID:
30026287
13.

Polycystic Kidney Disease, Autosomal Dominant.

Harris PC, Torres VE.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019.
2002 Jan 10 [updated 2018 Jul 19].

14.

Longitudinal Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney Disease.

Dad T, Abebe KZ, Bae KT, Comer D, Torres VE, Czarnecki PG, Schrier RW, Steinman TI, Moore CG, Chapman AB, Kaya D, Tao C, Braun WE, Winklhofer FT, Brosnahan G, Hogan MC, Miskulin DC, Rahbari Oskoui F, Flessner MF, Perrone RD.

Kidney Int Rep. 2018 Jan 6;3(3):619-624. doi: 10.1016/j.ekir.2017.12.011. eCollection 2018 May.

15.

Monoallelic Mutations to DNAJB11 Cause Atypical Autosomal-Dominant Polycystic Kidney Disease.

Cornec-Le Gall E, Olson RJ, Besse W, Heyer CM, Gainullin VG, Smith JM, Audrézet MP, Hopp K, Porath B, Shi B, Baheti S, Senum SR, Arroyo J, Madsen CD, Férec C, Joly D, Jouret F, Fikri-Benbrahim O, Charasse C, Coulibaly JM, Yu AS, Khalili K, Pei Y, Somlo S, Le Meur Y, Torres VE; Genkyst Study Group; HALT Progression of Polycystic Kidney Disease Group; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease, Harris PC.

Am J Hum Genet. 2018 May 3;102(5):832-844. doi: 10.1016/j.ajhg.2018.03.013. Epub 2018 Apr 26.

16.

Determinants of Progression in Early Autosomal Dominant Polycystic Kidney Disease: Is it Blood Pressure or Renin-Angiotensin-Aldosterone-System Blockade?

Brosnahan GM, Abebe KZ, Moore CG, Bae KT, Braun WE, Chapman AB, Flessner MF, Harris PC, Hogan MC, Perrone RD, Rahbari-Oskoui FF, Steinman TI, Torres VE, The Halt Pkd Investigators.

Curr Hypertens Rev. 2018;14(1):39-47. doi: 10.2174/1573402114666180322110209.

17.

The Value of Genetic Testing in Polycystic Kidney Diseases Illustrated by a Family With PKD2 and COL4A1 Mutations.

Cornec-Le Gall E, Chebib FT, Madsen CD, Senum SR, Heyer CM, Lanpher BC, Patterson MC, Albright RC, Yu AS, Torres VE; HALT Progression of Polycystic Kidney Disease Group Investigators, Harris PC.

Am J Kidney Dis. 2018 Aug;72(2):302-308. doi: 10.1053/j.ajkd.2017.11.015. Epub 2018 Feb 1.

PMID:
29395486
18.

Tolvaptan in Later-Stage Polycystic Kidney Disease.

Torres VE, Gansevoort RT, Czerwiec FS.

N Engl J Med. 2018 Feb 1;378(5):489-490. doi: 10.1056/NEJMc1716478. No abstract available.

PMID:
29385372
19.

Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials.

Brosnahan GM, Abebe KZ, Moore CG, Rahbari-Oskoui FF, Bae KT, Grantham JJ, Schrier RW, Braun WE, Chapman AB, Flessner MF, Harris PC, Hogan MC, Perrone RD, Miskulin DC, Steinman TI, Torres VE; HALT-PKD Trial Investigators.

Am J Kidney Dis. 2018 May;71(5):666-676. doi: 10.1053/j.ajkd.2017.10.023. Epub 2018 Jan 3.

PMID:
29306517
20.

Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease.

Yu ASL, Shen C, Landsittel DP, Harris PC, Torres VE, Mrug M, Bae KT, Grantham JJ, Rahbari-Oskoui FF, Flessner MF, Bennett WM, Chapman AB; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP).

Kidney Int. 2018 Mar;93(3):691-699. doi: 10.1016/j.kint.2017.09.027. Epub 2017 Dec 28.

21.

Autosomal Dominant Polycystic Kidney Patients May Be Predisposed to Various Cardiomyopathies.

Chebib FT, Hogan MC, El-Zoghby ZM, Irazabal MV, Senum SR, Heyer CM, Madsen CD, Cornec-Le Gall E, Behfar A, Harris PC, Torres VE.

Kidney Int Rep. 2017 Jun 6;2(5):913-923. doi: 10.1016/j.ekir.2017.05.014. eCollection 2017 Sep.

22.

ADPKD Progression in Patients With No Apparent Family History and No Mutation Detected by Sanger Sequencing.

Braun WE, Abebe KZ, Brosnahan G, Patterson CG, Chapman AB, Harris PC, Hogan MC, Perrone RD, Torres VE, Miskulin DC, Steinman TI, Winklhofer FT, Rahbari-Oskoui FF, Czarnecki PG, Bae KT, Grantham JJ, Flessner MF, Schrier RW.

Am J Kidney Dis. 2018 Feb;71(2):294-296. doi: 10.1053/j.ajkd.2017.09.008. Epub 2017 Dec 2. No abstract available.

23.

A Drug Development Tool for Trial Enrichment in Patients With Autosomal Dominant Polycystic Kidney Disease.

Perrone RD, Mouksassi MS, Romero K, Czerwiec FS, Chapman AB, Gitomer BY, Torres VE, Miskulin DC, Broadbent S, Marier JF.

Kidney Int Rep. 2017 Feb 21;2(3):451-460. doi: 10.1016/j.ekir.2017.02.011. eCollection 2017 May.

24.

Total Kidney Volume Is a Prognostic Biomarker of Renal Function Decline and Progression to End-Stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease.

Perrone RD, Mouksassi MS, Romero K, Czerwiec FS, Chapman AB, Gitomer BY, Torres VE, Miskulin DC, Broadbent S, Marier JF.

Kidney Int Rep. 2017 Jan 16;2(3):442-450. doi: 10.1016/j.ekir.2017.01.003. eCollection 2017 May. Erratum in: Kidney Int Rep. 2018 May 22;3(4):1015.

25.

Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease.

Nowak KL, You Z, Gitomer B, Brosnahan G, Torres VE, Chapman AB, Perrone RD, Steinman TI, Abebe KZ, Rahbari-Oskoui FF, Yu ASL, Harris PC, Bae KT, Hogan M, Miskulin D, Chonchol M.

J Am Soc Nephrol. 2018 Feb;29(2):571-578. doi: 10.1681/ASN.2017070819. Epub 2017 Nov 8.

26.

Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.

Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, Ouyang J, McQuade RD, Blais JD, Czerwiec FS, Sergeyeva O; REPRISE Trial Investigators.

N Engl J Med. 2017 Nov 16;377(20):1930-1942. doi: 10.1056/NEJMoa1710030. Epub 2017 Nov 4.

27.

Genetic Complexity of Autosomal Dominant Polycystic Kidney and Liver Diseases.

Cornec-Le Gall E, Torres VE, Harris PC.

J Am Soc Nephrol. 2018 Jan;29(1):13-23. doi: 10.1681/ASN.2017050483. Epub 2017 Oct 16.

28.

Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial.

Cornec-Le Gall E, Blais JD, Irazabal MV, Devuyst O, Gansevoort RT, Perrone RD, Chapman AB, Czerwiec FS, Ouyang J, Heyer CM, Senum SR, Le Meur Y, Torres VE, Harris PC.

Nephrol Dial Transplant. 2018 Apr 1;33(4):645-652. doi: 10.1093/ndt/gfx188.

29.

Common Elements in Rare Kidney Diseases: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Aymé S, Bockenhauer D, Day S, Devuyst O, Guay-Woodford LM, Ingelfinger JR, Klein JB, Knoers NVAM, Perrone RD, Roberts J, Schaefer F, Torres VE, Cheung M, Wheeler DC, Winkelmayer WC; Conference Participants.

Kidney Int. 2017 Oct;92(4):796-808. doi: 10.1016/j.kint.2017.06.018. Erratum in: Kidney Int. 2017 Dec;92(6):1558.

30.

Isolated polycystic liver disease genes define effectors of polycystin-1 function.

Besse W, Dong K, Choi J, Punia S, Fedeles SV, Choi M, Gallagher AR, Huang EB, Gulati A, Knight J, Mane S, Tahvanainen E, Tahvanainen P, Sanna-Cherchi S, Lifton RP, Watnick T, Pei YP, Torres VE, Somlo S.

J Clin Invest. 2017 Sep 1;127(9):3558. doi: 10.1172/JCI96729. Epub 2017 Sep 1.

31.

Generation and phenotypic characterization of Pde1a mutant mice.

Wang X, Yamada S, LaRiviere WB, Ye H, Bakeberg JL, Irazabal MV, Chebib FT, van Deursen J, Harris PC, Sussman CR, Behfar A, Ward CJ, Torres VE.

PLoS One. 2017 Jul 27;12(7):e0181087. doi: 10.1371/journal.pone.0181087. eCollection 2017.

32.

Quantitative MRI of kidneys in renal disease.

Kline TL, Edwards ME, Garg I, Irazabal MV, Korfiatis P, Harris PC, King BF, Torres VE, Venkatesh SK, Erickson BJ.

Abdom Radiol (NY). 2018 Mar;43(3):629-638. doi: 10.1007/s00261-017-1236-y.

33.

The regulatory 1α subunit of protein kinase A modulates renal cystogenesis.

Ye H, Wang X, Constans MM, Sussman CR, Chebib FT, Irazabal MV, Young WF Jr, Harris PC, Kirschner LS, Torres VE.

Am J Physiol Renal Physiol. 2017 Sep 1;313(3):F677-F686. doi: 10.1152/ajprenal.00119.2017. Epub 2017 Jun 14.

34.

Polycystic Kidney Disease and the Vasopressin Pathway.

van Gastel MDA, Torres VE.

Ann Nutr Metab. 2017;70 Suppl 1:43-50. doi: 10.1159/000463063. Epub 2017 Jun 15. Review.

35.

Performance of an Artificial Multi-observer Deep Neural Network for Fully Automated Segmentation of Polycystic Kidneys.

Kline TL, Korfiatis P, Edwards ME, Blais JD, Czerwiec FS, Harris PC, King BF, Torres VE, Erickson BJ.

J Digit Imaging. 2017 Aug;30(4):442-448. doi: 10.1007/s10278-017-9978-1.

36.

Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease.

Kline TL, Korfiatis P, Edwards ME, Bae KT, Yu A, Chapman AB, Mrug M, Grantham JJ, Landsittel D, Bennett WM, King BF, Harris PC, Torres VE, Erickson BJ; CRISP Investigators.

Kidney Int. 2017 Nov;92(5):1206-1216. doi: 10.1016/j.kint.2017.03.026. Epub 2017 May 20.

37.

Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials.

Brosnahan GM, Abebe KZ, Rahbari-Oskoui FF, Patterson CG, Bae KT, Schrier RW, Braun WE, Chapman AB, Flessner MF, Harris PC, Perrone RD, Steinman TI, Torres VE; HALT PKD Investigators.

Curr Hypertens Rev. 2017;13(2):109-120. doi: 10.2174/1573402113666170427142815.

38.

Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.

Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Dandurand A, Ouyang J, Czerwiec FS, Blais JD; TEMPO 4:4 Trial Investigators.

Nephrol Dial Transplant. 2017 Jul 1;32(7):1262. doi: 10.1093/ndt/gfx079. No abstract available.

PMID:
28444221
39.

B-type natriuretic peptide overexpression ameliorates hepatorenal fibrocystic disease in a rat model of polycystic kidney disease.

Holditch SJ, Schreiber CA, Harris PC, LaRusso NF, Ramirez-Alvarado M, Cataliotti A, Torres VE, Ikeda Y.

Kidney Int. 2017 Sep;92(3):657-668. doi: 10.1016/j.kint.2017.02.017. Epub 2017 Apr 14.

40.

Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.

Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Dandurand A, Ouyang J, Czerwiec FS, Blais JD; TEMPO 4:4 Trial Investigators.

Nephrol Dial Transplant. 2018 Mar 1;33(3):477-489. doi: 10.1093/ndt/gfx043.

41.

Isolated polycystic liver disease genes define effectors of polycystin-1 function.

Besse W, Dong K, Choi J, Punia S, Fedeles SV, Choi M, Gallagher AR, Huang EB, Gulati A, Knight J, Mane S, Tahvanainen E, Tahvanainen P, Sanna-Cherchi S, Lifton RP, Watnick T, Pei YP, Torres VE, Somlo S.

J Clin Invest. 2017 May 1;127(5):1772-1785. doi: 10.1172/JCI90129. Epub 2017 Apr 4. Erratum in: J Clin Invest. 2017 Sep 1;127(9):3558.

42.

Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 Trial.

Shoaf SE, Chapman AB, Torres VE, Ouyang J, Czerwiec FS.

J Clin Pharmacol. 2017 Jul;57(7):906-917. doi: 10.1002/jcph.880. Epub 2017 Feb 20.

43.

Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease.

Torres VE, Devuyst O, Chapman AB, Gansevoort RT, Perrone RD, Ouyang J, Blais JD, Czerwiec FS, Sergeyeva O; REPRISE Trial Investigators.

Am J Nephrol. 2017;45(3):257-266. doi: 10.1159/000456087. Epub 2017 Feb 7.

44.

Performance of the CKD-EPI Equation to Estimate GFR in a Longitudinal Study of Autosomal Dominant Polycystic Kidney Disease.

Shen C, Landsittel D, Irazabal MV, Yu AS, Chapman AB, Mrug M, Grantham JJ, Bae KT, Bennett WM, Flessner MF, Torres VE; CRISP Investigators.

Am J Kidney Dis. 2017 Mar;69(3):482-484. doi: 10.1053/j.ajkd.2016.10.021. Epub 2016 Dec 24. No abstract available.

45.

Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease.

Torres VE, Abebe KZ, Schrier RW, Perrone RD, Chapman AB, Yu AS, Braun WE, Steinman TI, Brosnahan G, Hogan MC, Rahbari FF, Grantham JJ, Bae KT, Moore CG, Flessner MF.

Kidney Int. 2017 Feb;91(2):493-500. doi: 10.1016/j.kint.2016.10.018. Epub 2016 Dec 16.

46.

Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial.

Devuyst O, Chapman AB, Gansevoort RT, Higashihara E, Perrone RD, Torres VE, Blais JD, Zhou W, Ouyang J, Czerwiec FS.

J Am Soc Nephrol. 2017 May;28(5):1592-1602. doi: 10.1681/ASN.2016040448. Epub 2016 Dec 5.

47.

Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial.

Casteleijn NF, Blais JD, Chapman AB, Czerwiec FS, Devuyst O, Higashihara E, Leliveld AM, Ouyang J, Perrone RD, Torres VE, Gansevoort RT; TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes) 3:4 Trial Investigators.

Am J Kidney Dis. 2017 Feb;69(2):210-219. doi: 10.1053/j.ajkd.2016.08.028. Epub 2016 Nov 14.

48.

Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial.

Gansevoort RT, Meijer E, Chapman AB, Czerwiec FS, Devuyst O, Grantham JJ, Higashihara E, Krasa HB, Ouyang J, Perrone RD, Torres VE; TEMPO 3:4 Investigators.

Nephrol Dial Transplant. 2016 Nov;31(11):1887-1894. Epub 2015 Dec 17.

49.

Automated segmentation of liver and liver cysts from bounded abdominal MR images in patients with autosomal dominant polycystic kidney disease.

Kim Y, Bae SK, Cheng T, Tao C, Ge Y, Chapman AB, Torres VE, Yu AS, Mrug M, Bennett WM, Flessner MF, Landsittel DP, Bae KT.

Phys Med Biol. 2016 Nov 21;61(22):7864-7880. Epub 2016 Oct 25.

50.

The importance of total kidney volume in evaluating progression of polycystic kidney disease.

Grantham JJ, Torres VE.

Nat Rev Nephrol. 2016 Nov;12(11):667-677. doi: 10.1038/nrneph.2016.135. Epub 2016 Oct 3. Review.

Supplemental Content

Loading ...
Support Center